Christian T Dietzel1, Christoph Schäfer2, Dirk Vordermark3. 1. Universitätslinik und Poliklinik für Strahlentherapie, Klinikum der Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany. christian.dietzel@uk-halle.de. 2. Universitätsklinik und Poliklinik für Innere Medizin II, Klinikum der Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Str. 40, 06120, Halle (Saale), Germany. 3. Universitätslinik und Poliklinik für Strahlentherapie, Klinikum der Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany.
Abstract
BACKGROUND: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory disease, which lacks an infectious genesis and predominantly involves the metaphysis of long bones. Common treatments range from nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids at first onset of disease, to immunosuppressive drugs and bisphosphonates in cases of insufficient remission. The therapeutic use of low-dose radiotherapy for CRMO constitutes a novelty. CASE REPORT: A 67-year-old female patient presented with radiologically proven CRMO affecting the right tibia/talus and no response to immunosuppressive therapy. Two treatment series of radiation therapy were applied with an interval of 6 weeks. Each series contained six fractions (three fractions per week) with single doses of 0.5 Gy, thus the total applied dose was 6 Gy. Ten months later, pain and symptoms of osteomyelitis had completely vanished. CONCLUSION: Radiotherapy seems to be an efficient and feasible complementary treatment option for conventional treatment refractory CRMO in adulthood. The application of low doses per fraction is justified by the inflammatory pathomechanism of disease.
BACKGROUND: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory disease, which lacks an infectious genesis and predominantly involves the metaphysis of long bones. Common treatments range from nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids at first onset of disease, to immunosuppressive drugs and bisphosphonates in cases of insufficient remission. The therapeutic use of low-dose radiotherapy for CRMO constitutes a novelty. CASE REPORT: A 67-year-old female patient presented with radiologically proven CRMO affecting the right tibia/talus and no response to immunosuppressive therapy. Two treatment series of radiation therapy were applied with an interval of 6 weeks. Each series contained six fractions (three fractions per week) with single doses of 0.5 Gy, thus the total applied dose was 6 Gy. Ten months later, pain and symptoms of osteomyelitis had completely vanished. CONCLUSION: Radiotherapy seems to be an efficient and feasible complementary treatment option for conventional treatment refractory CRMO in adulthood. The application of low doses per fraction is justified by the inflammatory pathomechanism of disease.
Authors: Marcus Niewald; M Heinrich Seegenschmiedt; Oliver Micke; Stefan Graeber; Ralf Muecke; Vera Schaefer; Christine Scheid; Jochen Fleckenstein; Norbert Licht; Christian Ruebe Journal: Int J Radiat Oncol Biol Phys Date: 2012-07-25 Impact factor: 7.038
Authors: Annette F Jansson; Thomas H Müller; Leonhard Gliera; Donna Pauler Ankerst; U Wintergerst; Bernd H Belohradsky; Volkmar Jansson Journal: Arthritis Rheum Date: 2009-04
Authors: Oliver J Ott; Oliver Micke; Ralph Mücke; Marcus Niewald; Franz Rödel; Ulrich Schäfer; M H Seegenschmiedt; Meritxell Arenas; Benjamin Frey; Udo S Gaipl Journal: Strahlenther Onkol Date: 2018-12-18 Impact factor: 3.621
Authors: Matthias G Hautmann; Philipp Rechner; Matthias Hipp; Ulrich Neumaier; Felix Steger; Fabian Pohl; Markus Weber; Oliver Kölbl; Christoph Süß Journal: Strahlenther Onkol Date: 2019-07-25 Impact factor: 3.621
Authors: Matthias G Hautmann; Ernst-Michael Jung; Lukas P Beyer; Christoph Süß; Felix Steger; Markus Weber; Fabian Pohl; Oliver Kölbl; Franz Josef Putz Journal: Strahlenther Onkol Date: 2018-10-30 Impact factor: 3.621